These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10963203)

  • 1. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
    Wagner SN; Rebmann V; Willers CP; Grosse-Wilde H; Goos M
    Lancet; 2000 Jul; 356(9225):220-1. PubMed ID: 10963203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
    Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
    Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
    Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
    Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.
    Fluck M; Kamanabrou D; Lippold A; Reitz M; Atzpodien J
    Cancer Biother Radiopharm; 2005 Jun; 20(3):280-9. PubMed ID: 15989473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma.
    Reintgen D; Rapaport D; Tanabe KK; Ross M
    J Fla Med Assoc; 1997 Mar; 84(3):188-93. PubMed ID: 9143171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
    Certa U; Seiler M; Padovan E; Spagnoli GC
    Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
    Donnelly S
    Oncol Nurs Forum; 1998 Jun; 25(5):921-7. PubMed ID: 9644709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
    Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
    Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
    Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC
    Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 19. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-G in melanoma: A new strategy to escape from immunosurveillance?
    Ugurel S; Reinhold U; Tilgen W
    Onkologie; 2002 Apr; 25(2):129-34. PubMed ID: 12006763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.